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Human T cell glycosylation and implications on immune therapy for cancer
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ABSTRACT
Glycosylation is an important post-translational modification, giving rise to a diverse and abundant
repertoire of glycans on the cell surface, collectively known as the glycome. When focusing on
immunity, glycans are indispensable in virtually all signaling and cell-cell interactions. More specifically,
glycans have been shown to regulate key pathophysiological steps within T cell biology such as T cell
development, thymocyte selection, T cell activity and signaling as well as T cell differentiation and
proliferation. They are of major importance in determining the interaction of human T cells with tumor
cells. In this review, we will describe the role of glycosylation of human T cells in more depth, elaborate
on the importance of glycosylation in the interaction of human T cells with tumor cells and discuss the
potential of cancer immunotherapies that are based on manipulating the glycome functions at the
tumor immune interface.
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Introduction
Mammalian glycosylation
Glycosylation is the enzymatic process that leads to the for-
mation of glycosidic linkages between carbohydrates and
other carbohydrates, proteins or lipids. Next to proteolytic
cleavage and modification of disulfide bonds, glycosylation is
an important post-translational modification that gives rise to
a diverse and abundant repertoire of glycans on the cell sur-
face, collectively known as the glycome.1–3 Known human
glycans are formed almost exclusively from only ten mono-
saccharide building blocks (L-fucose, D-galactose, N-acetyl-
D-galactosamine (GalNAc), N-acetyl-D-glucosamine
(GlcNAc), D-glucuronic acid, D-iduronic acid, D-mannose,
N-acetylneuraminic acid and D-xylose), which can be mod-
ified in particular glycoconjugates with sulfation, phosphory-
lation or de-acetylation. Through the orchestrated action of
a diverse set of glycosyltransferases, glycosidases, glycan phos-
phorylases and polysaccharide lyases, a large diversity of
mammalian glycans is generated. The biosynthesis of glycans
is primarily determined by glycosyltransferases, enzymes that
use activated sugar nucleotides or dolichol-phosphate bound
donors as substrate in the enzymatic formation of glycosidic
linkages to initiate, extend and diversify glycan structures. The
expression of these glycosyltransferases is often highly regu-
lated in a cell-type specific manner that changes during devel-
opment, differentiation and activation, implying that changes
in the glycome can occur in response to environmental and
genetic stimuli.4 However, the exact regulation of glycan
synthesis is still not completely understood, and this is mainly
due to the complexity inherent to the macromolecule itself
and its nontemplated mode of biosynthesis.5 The latter means
that genomic information is not just ‘decoded’ by the ribo-
some translating the linear DNA code to a linear product, but
that genomic information is ‘translated’ by a combination of
transcriptional and membrane transport processes into
a specific Golgi configuration.6
The most frequently occurring types of mammalian pro-
tein glycosylation are N- and mucin type O-linked glycosyla-
tion and they lead to a large structural repertoire of glycans
present on nearly every secreted and integral membrane pro-
tein. N-glycans are relatively bulky structures of which the
synthesis starts on a lipid precursor at the cytoplasmic face of
the endoplasmic reticulum (ER). After transfer to the ER
lumen by an ER-resident flippase and further addition of
monosaccharides, the glycan is transferred to nascent poly-
peptides at the side-chain amide nitrogen on asparagine resi-
dues in an N-x-S/T consensus sequence. After playing its role
in protein folding quality control, the glycan is trimmed to
a high mannose type structure carrying terminal mannoses.
After transport from the ER to the Golgi apparatus (GA), the
glycan can be further trimmed. At this point, these oligoman-
nose glycans can remain unchanged, but most are subse-
quently rebuilt into hybrid and complex type glycans by the
sequential action of GA resident glycosyltransferases.
Typically, N-glycans develop into structures with at least two
branches.
In contrast to N-glycans, O-glycans and protein-linked
glycosaminoglycans (proteoglycans) are de novo synthe-
sized, directly on the folded protein. This process is
initiated in the GA, by the addition of D-GalNAc (mucin
type O-glycans) or D-xylose (proteoglycans) to the side-
chain hydroxyl group of serine or threonine.
Subsequently, the glycans are turned into mature structures
by the sequential action of a host of Golgi-resident
enzymes. For mucin type O-glycans, this leads to a variety
of core structures differing in their carbohydrate composi-
tion and linkage to the protein-proximal GalNAc residue,
CONTACT Nele Festjens nele.festjens@vib-ugent.be Technologiepark-Zwijnaarde 71, Zwijnaarde 9052
HUMAN VACCINES & IMMUNOTHERAPEUTICS
https://doi.org/10.1080/21645515.2020.1730658
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
which are further extended and capped with similar struc-
tures as for N-glycans. (Figure 1)
The glycans produced in the GA obviously depend on the
repertoire of glycosylation enzymes present and their kinetic
rate constants. Examination of transcripts encoding specific
enzymatic machinery for glycan biosynthesis showed that
many, but not all, changes in glycan abundance result from
alterations in transcript expression of corresponding biosyn-
thetic enzymes.8,9 This suggests that transcriptional regulation
contributes significantly to the regulation of glycan expression.
Besides, systems glycobiology approaches have shown that
additional factors and parameters of regulation should be con-
sidered, including processes regulating the localization of
enzymes in the Golgi, the availability of substrates, enzyme
kinetics….10,11 The role of the GA in the translation of genome
to glycome has been extensively reviewed in ref.6 and will not
further be discussed in this review.We can generally state that the
relative abundance of glycans in the total glycan composition of
a cell or tissue is in part dependent on the competition between
glycosyltransferases with different activated donor substrate spe-
cificities for a certain glycoprotein acceptor. Furthermore, the
concentration of sugar nucleotide donors, the association with
specific chaperones, the modification or removal of sugars by
additional enzymes and the trafficking dynamics of the acceptor
glycoprotein throughout the secretory pathway are important
factors contributing to the broad variety of glycans present on
a cell.6,12
When focusing on immunity, glycans are indispensable in
virtually all signaling and cell-cell interactions. Glycan signa-
tures present on healthy, inflamed or malignant tissue, or
pathogens, provide signals for “self” or “non-self” recognition
and are increasingly appreciated as key molecules in regulat-
ing immunity versus tolerance.
For example, during the initiation of innate immune
responses, the microbial molecular patterns that are recog-
nized often are glycoconjugates. In adaptive immunity,
Figure 1. Overview of human N- and O-glycosylation in the Golgi apparatus. On the left side, the synthesis of a human glycoprotein with several relevant complex-
type N-glycans is shown. In the cis Golgi, mannosidase I (ManI) activity leads to a Man5GlcNAc2 that can be further modified in the medial Golgi.
N-acetylglucosaminyltransferase I (GnTI) activity commits the glycan to the complex or hybrid type. Mannosidase II (ManII) activity, followed by several
N-acetylglucosaminyltransferases then further commits the glycan to the complex type. If only N-acetylglucosaminyltransferases II (GnTII) acts on it, the result is
a biantennary complex type N-glycan. GnTIV and/or GnTV activity then generates different triantennary or a tetraantennary complex type glycan. Fucosyltransferase
VIII (FucTVIII) can act on any complex or hybrid type glycan to add a core α-1,6-fucose in the medial Golgi. Afterward, in the trans Golgi, galactosyltransferases (GalT),
fucosyltransferases (FucT), sialyltransferases (SiaT) or a combination of GnTs and GalTs synthesize different capping moieties (sialylation, poly-LacNAc repeats, Lewis
antigens) on N-glycans.
The right side of the figure shows mucin-type O-glycosylation biosynthesis. Polypeptide-GalNAc-transferases (ppGalNAcTs) initiate O-glycosylation in the cis Golgi,
which is followed by the action of one or two core synthesizing enzymes: core 1 galactosyltransferase (C1GalT), core 2 N-acetylglucosaminidase I, II or III (C2GnTI/II/III)
and core 3 N-acetylglucosaminidase (C3GnT), resulting in the synthesis of four so-called core structures. Core 1 and 2 are common, while core 3 and 4 have
a restricted expression pattern. Two SiaT activities in particular (ST6GalNAc and ST3Gal) can add N-Acetylneuraminic acid to the Tn antigen or core 1 (T antigen) to
generate the sialyl-Tn or sialyl-T antigen (STn or ST antigen). Several GalTs, GnTs, FucTs and SiaTs can act on the core structures to introduce further branching and
terminating structures (not shown). Note that four more core structures (core 5–8) are known, but since their occurrence is extremely rare, they are not shown here.
This figure has been adapted from De Wachter et al. with permission.7
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glycans are involved in the alignment of the immunological
synapse, in the generation and loading of antigenic peptides
into MHC class I and in MHC class II antigen processing.
These effects of glycans on immunity are reviewed by Baum
et al.13 In this review, we will focus on the role of glycans in
human T cell homeostasis and their function in T cell immu-
notherapy for cancer (Figure 2).
Glycan-binding proteins
In most cases, no single function can be attributed to
a specific type of glycan. The function of a glycan is highly
specific to the glycoprotein to which it is linked and the
density at which it is present on a protein or on a biological
surface, and it often relies upon the binding to glycan-
binding proteins (GBPs). GBPs are characterized by one or
more carbohydrate recognition domains and are often oli-
gomeric or membrane bound. As the interactions between
monosaccharides and proteins are often intrinsically weak,
GBPs engage in multivalent interactions in order to confer
avidity and specificity to their binding interactions with
larger glycan structures or glycan-carrying surfaces, while
their interactions are still tunable by alterations in the den-
sity of the glyco-epitopes to which they bind. GBPs are
present in all organisms, ranging from microbes to humans
and are involved in diverse biological processes, including
immune responses. It will become clear from the following
paragraphs that a particular glycan can be bound by several
GBPs, and thus exerting pleiotropic effects. Since we will
focus on the role of glycans and GBPs in human T cell
function, we will first briefly introduce three types of
GBPs with important roles in T cell responses.
Galectins
Galectins are a type of soluble, mammalian glycan-binding
proteins grouped because of their common carbohydrate
recognition domain (CRD) structure. It is because of varia-
tions in the amino acid sequence of this CRD that distinct
Galectins have different glycan ligand specificities. As such, 16
different Galectins can be discerned.14 N-acetyllactosamine is
the ligand recognized by Galectins on the glycan moiety on
both glycolipids and glycoproteins. The affinity of these inter-
actions is proportional to the N-acetyllactosamine content of
the glycoprotein or -lipid and the fine glycan structure. The
spatial organization and modifications by glycosyltransferases
are also contributing to the specificity of the interaction. For
example, incorporation of fucose slightly improves Galectin-1
and Galectin-3 binding.15
Galectins exert a broad range of effects during all aspects of
T cell mediated immunity by the formation of lattices on the
T cell surface.16 In this way, they serve both to amplify or
resolve immune responses. The precise effect varies depend-
ing on the tissue context, the intracellular or extracellular
localization of the Galectin, the (patho)physiological condi-
tion and the presence of other regulatory mechanisms.
Galectin-1, −3 and −9 are the main Galectins affecting T cell
function, as will be discussed further below.
Selectins
Selectins are a subtype of C-type Lectin receptors (CLRs),
membrane anchored GBPs which bind to sialylated, fucosy-
lated or sulfated glycans, mainly on the O-glycan chains of
glycoproteins or proteoglycans and on glycolipids. Selectins
can be further subdivided into E-, P- and L-Selectin based on
their expression profile and the glycan ligands to which they
bind. While during inflammation, L-Selectin expression is
induced in leukocytes, the expression of E-Selectin is induced
on the vascular endothelium, and P-Selectin expression or
translocation is induced on both vascular endothelium and
platelets respectively. E- and P-Selectin bind sLex antigen
(sialylated, fucosylated lactosamine core structures – sLex).
The major glycoprotein ligand for P-Selectin, termed
P-Selectin glycoprotein ligand-1 (PSGL-1), has sulfated tyro-
sine residues adjacent to a core-2-based O-glycan expressing
SLex.17 Ligands for L-Selectin contain 6-sulfo-sLex moieties on
mucin-type O-glycans and N-glycans. Synthesis of the Selectin
ligands mainly depends on the expression of the relevant
fucosyl- and sialyltransferases. In the absence of these
enzymes, lymphocyte homing to peripheral lymph nodes or
sites of inflammation is strongly attenuated.18,19
Siglecs
Siglecs (sialic acid-binding immunoglobulin-type lectins) are
a family of immune regulatory receptors predominantly found
on the cells of the hematopoietic system. They have different
binding preferences for sialylated glycan ligands. Siglecs are
categorized into two subgroups that are functionally diverse,
even in terms of signaling mechanisms. One group includes
the structurally conserved Siglecs consisting of Siglec-1
(Sialoadhesin), Siglec-2 (CD22), Siglec-4 (myelin-associated
glycoprotein, MAG) and Siglec-15. Another subgroup
includes Siglec 3/CD33 and CD33-related Siglecs which have
high homology to CD33 in their extracellular domains, con-
tain at least one classic immunoreceptor tyrosine-based inhi-
bition motif (ITIM) and show high variability in number
between species and even vary between individuals of the
same species, e.g. in humans. There is no evidence for
a significant degree of functional redundancy either in the
Siglecs conserved across species or in the CD33-related group
of Siglecs. Most Siglecs function as inhibitory receptors on
innate and adaptive immune cells. Binding to and subsequent
signaling by both cis-ligands (expressed on the same cells;
considered markers of ‘self’) as well as to sialoglycoconjugates
presented in trans (e.g. on a neighboring cell or pathogen)
attenuates immune responses.20
Glycosylation in human T cell homeostasis
Role of glycosylation in T cell development
Glycans regulate key physiological steps within T cell biology
such as T cell development and thymocyte selection, T cell
activity and signaling as well as T cell differentiation and
proliferation (Table 1).
T cell migration is thought to be largely dictated by
O-glycan modifications on Selectin ligands.29 Before they
can populate peripheral tissues, hematopoietically derived
HUMAN VACCINES & IMMUNOTHERAPEUTICS 3
T cell precursors exit the bone marrow and must home to the
thymus to mature from the double negative (DN) state toward
double positive (DP) and undergo positive and negative selec-
tion to mature into either a CD4+ or CD8+ T cell. This
homing is dependent on P-Selectin expression on thymic
endothelial cells and the ability of T cell precursors to gen-
erate P-Selectin ligands.48 Trafficking of T cell precursors to
the thymus is impaired in the absence of PSGL-1 glycan
fucosylation (α-1,3) since the latter is required for binding
to P-Selectin on thymic epithelium.49
The early thymic progenitor cells are CD4 and CD8 DN,
and are also T cell receptor (TCR) negative. DN1 cells can
give rise to T cells, NK cells, B cells, and macrophages. TCR
rearrangement begins in DN2 cells. Commitment to the
T cell lineage occurs during the transition from the DN2
to the DN3 stage. DN3 cells that have successfully rear-
ranged their TCRβ-chain, form a pre-TCR complex with
a pre-TCRα chain. This pre-TCR enforces β-selection and
supports proliferation and differentiation bringing cells from
DN3 to DN4. DN4 cells upregulate CD8 and CD4 to become
DP and initiate rearrangement of the TCRα locus. After
successful rearrangement, a TCRαβ complex is expressed
on DPs that undergo positive or negative selection and
become MHC class I or II restricted. This process upregu-
lates glucose and glutamine uptake with a concomitant
increase in O-GlcNAc levels.21
O-GlcNAcylation has been shown to be required through-
out T cell development.50
Mice that are conditionally knockout for Ogt in DN thy-
mocytes, contain substantially less thymocytes and mature
CD4+ and CD8+ T cells, a phenotype consistent with a loss
of β-selection.21 Deletion of Ogt just before the DP stage,
causes failure to differentiate to mature single positive (SP)
CD4+ or CD8+ T cells, although numbers of DP cells are not
influenced.21 Increased expression of OGT in T cells from
women with active lupus highlights the importance of
O-GlcNAc regulation for normal immune homeostasis.22
During T cell maturation from DP thymocytes into SP
T cells, both α(−2,3)- and α(−2,6)-sialylation of cell surface
glycoproteins is increased, as is experimentally shown by
increased Sambucus nigra lectin (SNA) binding (specific for
α(−2,6)-sialylation) and decreased peanut agglutinin (PNA)
binding (specific for non-sialylated core-1 O-glycans).23,24
These findings are confirmed in β-Galactoside-α-
2,6-Sialyltransferase 1 (ST6 GalI)-deficient mice, where DN
populations are reduced, whereas a reduction in mature CD8+
SP thymocytes is demonstrated in ST3 GalI-deficient mice
(reduced sialylation of core 1 O-linked glycans).25
Following their development and exit from the thymus,
naive T cells enter the periphery where they continually sur-
vey the spleen and secondary lymphoid organs for an encoun-
ter with cognate antigen. Increased sialic-acid modifications
Table 1. Role of T cell glycosylation during T cell development, activation and signaling.
Glycosylation Effect
T-CELL DEVELOPMENT α-(1,3) fucosylation of PSGL-1 ● Homing of T cell precursors to the thymus (P-Selectin binding)18,19
O-GlcNAcylation by OGT ● β-selection, maturation of single positive CD4+ and CD8+ T cells21,22
α-(2,3) and α-(2,6) sialylation of cell
surface glycoproteins
● Maturation of single positive CD4+ and CD8+ T cells23-25
● Regulation of TCR affinity-dependent negative selection16,26-28
Core 2 O-glycosylation ● Extravasation across activated vascular endothelium and entry in non-
lymphoid tissue29,30
T CELL ACTIVATION AND SIGNALING N-glycan branching by MGAT5 ● Increased N-acetyllactosamine modifications (ligand of Galectins)
● Binding by Galectins holds CD45 and TCR signaling complex in close proximity
to prevent low-avidity T cell activation31,32
● Promotion of Th2 development over Th1 responses33
● N-glycan branching on CTLA-4 enhances its retention at the T cell surface,
suppressing T cell activation and promoting immune tolerance34-36
N-Glycosylation of MHCI ● Important for protein folding, trafficking and peptide loading37-40
N-Glycosylation of MHCII ● Modulation of glycopeptide binding and presentation41-44
α-(2,6) sialylation of CD45 ● Capping of the terminal Gal-β-1,4-GlcNAc-binding sites, used as a ligand by
Galectin-1, with consequent reduced Galectin-1 induced cell death
● Inhibition of CD45 clustering, leading to diminished signaling45
N-Glycan branching of CD25 ● Increased surface expression and retention, thereby controlling T cell
differentiation46
O-GlcNAcylation of transcription
factors involved in IL2-signaling
● Regulation of IL-2 production upon TCR stimulation21
Sialylation of CCR7 receptor ● Modulation of T cell homing to the lymph nodes. Sialylation provides steric
hindrance for ligand binding, diminishing receptor potency and decreasing
signaling ability; reflected by low CCR7 sialylation on recirculating T cells and
high CCR7 sialylation on activated T cells47
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of glycans on differentiated SP CD8+ thymic T cells decrease
the binding avidity of CD8 for MHC I molecules, thereby
regulating TCR affinity-dependent negative selection.16,26–28
Naive T cells express high levels of L-Selectin (CD62L) and
are defined as being CD44lo/CD62Lhi in mice and CD45RA+/
CD62Lhi in humans. Once a naive T cell is activated by
antigen binding and co-stimulation, CD62L expression ceases
and T cells become effector cells, most of them having
a limited life span. Those that survive become long-lived
memory T cells, which are characterized by 2 subsets, being
central memory (TCM, CD62L
+ CCR7+) or effector memory
(TEM, CD62L
− CCR7−) T cells. TCM actively survey lymph
nodes due to the presence of L-Selectin, whereas TEM are
limited to the circulation, spleen and non-lymphoid tissues
due to its absence.
Naive T cells cannot synthesize core 2 O-glycans or bind to
P (CD62P)- and E-Selectin (CD62E), which essentially
excludes them from entering non-lymphoid tissues.
Following stimulation of the T cell receptor, both CD8+ and
CD4+ T cells increase expression of core 2 β-
1,6-N-acetylglucosaminyltransferase-I (GCNT1), α-1,3-fuco-
syltransferase-VII (FUT7), and likely additional enzymes that
facilitate core 2 O-glycan synthesis. This post-translational
modification transforms surface proteins such as PSGL-1
and CD43 into P- and E-Selectin ligands to direct extravasa-
tion across activated vascular endothelium and entry into
non-lymphoid tissues. Effector CD8+ T cells have increased
binding to PNA, indicating lowered capping of core 1
O-glycans with α-2,3-linked sialic acids.29,30
Role of glycosylation in T cell activation
Glycosylation is also involved in the regulation of T cell
activation and functioning, mainly by N-glycosylation of the
TCR and co-receptors (Table 1). Glycans can act to stabilize
complexes at the immunological synapses, serving as
a protective coat for the underlying protein by inhibiting
degradation by proteases. They can suppress aggregation of
TCRs on the membrane, thereby reducing auto-activation.51
Initiation of T cell responses depends on the recognition of
an antigenic epitope presented in the context of a class I or
class II MHC (MHCI/II) molecule. Glycans on both the
TCRαβ chains and MHCII can impact T cell activation.
N-glycans present on the TCR are thought to play a role in
cell surface localization and the orientation and organization
of the molecule itself rather than directly influencing MHC
interactions.
β-1,6-N-acetylglucosaminyltransferase-V (MGAT5) is the
enzyme responsible for the initiation of GlcNAc-β-(1,6)-
branching on N-glycans and is involved in multiple aspects
of T cell activation. β-(1,6)-N-glycan branching leads to an
increase in N-acetyllactosamine modifications, the ligand of
Galectins. It has been demonstrated that absence of Mgat5
and thus a decrease in N-acetyllactosamine, lowers T cell
activation thresholds in vitro by enhancing TCR clustering
due to the absence of Galectin-glycoprotein lattice
formation.31 This Galectin-mediated lattice is responsible for
holding CD45 and the TCR signaling complex in close proxi-
mity via their O- and N-linked glycans (respectively) to
prevent low-avidity T cell activation.32 Along the same line,
an increased incidence of autoimmune disease is seen in the
absence of Mgat5 in vivo.52 Furthermore, negative regulation
of TCR signaling by β-1,6-GlcNAc-containing N-glycans pro-
motes development of Th2 over Th1 responses, enhances Th2
polarization, and suggests a mechanism for the increased
autoimmune disease susceptibility observed in Mgat5−/-
mice.33 On the other hand, Mgat5 expression can be induced
by the anti–inflammatory cytokine IL-10, decreasing antigen
sensitivity of CD8+ T cells during chronic infection.53
N-glycans on MHCI are important for protein folding and
trafficking to the cell surface and peptide loading of MHCI
molecules.37–40 MHCI molecules are heterodimers comprised
of a polymorphic transmembrane heavy chain and non-
glycosylated β2-microglobulin. Within the heavy chain, the
single conserved site for N-glycosylation across all known
alleles is Asn86. The relative homogeneity of the complex
type N-glycans on human MHCI suggests that the glycan
might play a role in differentiating self and non-self,54 however,
this possibility remains unexplored.
MHCII has three highly conserved N-glycosylation sites,
two on the α-chain (Asn78 and Asn118) and one on the β-
chain (Asn19). Glycosylation of MHCII is not required for
proper folding or trafficking of MHCII and shows a great
variety between different cell types (e.g.: DC vs. B cell vs.
macrophage), such as differences in degree of terminal sialy-
lation and branching patterns which can directly modulate
glycopeptide binding and presentation,41–44 while this has no
impact on binding of unmodified peptide antigens. It is
speculated that the glycans serve to extend the binding plat-
form of MHCII to accommodate the larger glycoantigen
molecules.
Glycosylation of transmembrane T cell surface proteins
CD43 and CD45 are the two most abundant glycoproteins
present on the T cell surface and are expressed throughout all
stages of T cell development, from DN thymocytes to mem-
ory T cells. CD43 and CD45 are decorated with O- and
N-glycans, and these molecules function in T cell activation,
differentiation and migration, T cell receptor signaling and
T cell apoptosis.55 Alternatively spliced isoforms of CD45
display different glycosylation sites. The expression of
ST6GalI transferase has been proposed to modulate binding
of Galectin-1 to CD45 on T cells;45 α-2,6-sialylation of CD45
glycans caps the terminal Gal-β-1,4-GlcNAc-binding sites
used as a ligand by Galectin-1, implying that reduced
ST6GalI expression in activated T cells could lead to
increased binding of Galectin-1, resulting in cell death.
Furthermore, α-2,6-sialylation was shown to inhibit cluster-
ing of CD45 on T cells, leading to diminished signaling
(Table 1).45
CD25 is the high-affinity alpha subunit of the IL-2 receptor
and surface expression and retention is modulated by
N-glycan branching, thereby controlling T cell differentiation
with impact on immune tolerance.46 Abolishing complex and
hybrid type N-glycosylation in favor of the oligomannose type
on CD25 via Mgat1 deletion reduced surface expression and
retention while upregulation of branching via GlcNac
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supplementation or Mgat5 overexpression had the opposite
effect, by raising CD25 surface levels. Increased β-
1,5-N-glycan branching on CD25 also skews IL-2 signaling
toward iTreg differentiation over Th17 differentiation.46
Furthermore, transcription factors both upstream (e.g.
NFAT and NFκb),56,57 and downstream (cMyc) of IL-2 sig-
naling require O-GlcNAc modifications for proper function.21
For example, chemical inhibition of OGT in primary human
T cells decreases production of IL-2 upon TCR stimulation.
Lymph node homing of T cells and antigen-experienced DCs
relies on the chemokine receptor CCR7 and its two ligands,
CCL19 and CCL21. Leukocyte subsets express distinct pat-
terns of sialylation of the human CCR7.47 This sialylation
provides steric hindrance for ligand binding, rendering the
receptor less efficient at low chemokine concentrations. DCs
secrete glycosidase that deglycosylates CCR7 on T cells,
thereby enhancing receptor potency and increasing its signal-
ing ability, while inhibiting receptor endocytosis.47 Consistent
with this finding is the observation that naive, recirculating
T cells only express limited amounts of sialylated CCR7,
whereas high levels are seen on activated T cells.
Glycosylation of the receptor acts as a swinging door, provid-
ing on the one hand steric hindrance for chemokine binding
and on the other hand, retaining bound chemokines within
the binding pocket, keeping the receptor susceptible for
desensitization.
Importance of glycosylation in the interaction of
human T cells with tumor cells
One of the hallmarks of cancer biology is the altered tumor
cell glycosylation characterized by enhanced branching and
sialylation and incomplete glycan synthesis. Virtually all can-
cer types are associated with expression of common glycan
epitopes such as Sia-Lex and Sia-Lea. Expression of these
Siglec/Selectin ligands is correlated with enhanced metastasis
and poor prognosis of cancer patients suffering from colon,
gastric, prostate, renal, pancreatic or lung cancer.58–60
Moreover, neo-antigens originate through glycosylation of
tumor proteins, serving as targets for tumor-specific
T cells.61,62 In this paragraph, we will highlight the impor-
tance of glycosylation in the interaction of human T cells with
tumor cells, often contributing to the creation of T cell killing
resistance pathways in cancer.
Immune checkpoints
It is well established that tumors are inherently immunosup-
pressive, both due to the expression of immune checkpoint
molecules (e.g. programmed death ligand-1, PD-L1) and
expression of immune-inhibitory molecules (e.g. anti–inflam-
matory cytokines and chemokines). Unlike CTLA-4 or pro-
grammed cell death protein-1 (PD-1), which are primarily
expressed on immune cells, PD-L1 is expressed in cancer
cells and macrophages and plays a major role in inhibiting
the immune response. Binding of PD-L1 to its receptor, PD-1
on T cells, inhibits T cell proliferation, cytokine production
and cytolytic activity. The majority of PD-L1 on human
tumor tissues and cancer cell lines is glycosylated, which
stabilizes the PD-L1 protein, thus strengthening inhibition of
the immune response.63,64
Growth arrest of activated T cells is dependent on induc-
tion of the immune checkpoint cell surface cytotoxic
T-lymphocyte-associated-antigen-4 (CTLA-4). CTLA-4 com-
petes with the sequence-related receptor CD28 for CD80/86
ligand on antigen-presenting cells to positively (in the case of
CD28) or negatively (in the case of CTLA-4) regulate T cell
proliferation.65 TCR activation signaling normally leads to
increased Mgat5 activity and N-glycan branching. It was
demonstrated that in Mgat5−/- T cells, the fractions of
T cells expressing CTLA-4 on their cell surfaces, as well as
the CTLA-4 expression levels are decreased following low
levels of TCR stimulation while CD28 surface levels are com-
parable in Mgat5−/- vs WT T cells.34 On the contrary,
increased N-glycan branching on CTLA-4 molecules upon
TCR activation is shown to enhance its retention at the
T cell surface, thereby suppressing T cell activation and pro-
moting immune tolerance (Table 1).35,36
Tim-3 is an immune checkpoint receptor that shares
a similar expression pattern as PD-1 on T cells. Tim-3 is
a coinhibitory receptor, meaning that ligand binding leads to
inhibition of T cell proliferation and cytokine production.
T cell mediated immunity is further regulated through the
interaction of Tim-3 with Galectin-9 (see further).66
Galectins
Galectin-9 is one of the ligands of Tim-3 and negatively
regulates T cell immunity.67 A recent study shows that the
interaction between Tim-3, expressed on T cells and Galectin-
9, expressed in the tumor environment, is implicated in the
resistance to PD-1 blockade in cancer patients (Table 2).78
Furthermore, increased serum levels of Galectin-9 and Tim-3
were observed in the plasma of patients with acute myeloid
leukemia and chronic lymphocytic leukemia, turning
Galectin-9 into a potential target in leukemia.79–81
Galectin-1 functioning is involved in many signaling path-
ways leading to anti–inflammatory activities by targeting mul-
tiple types of immune cells.68 In T cells, it is controlling T cell
effector function homeostasis by regulating activation, differ-
entiation, survival and cytokine production.69 Galectin-1 is
known to be a pro-tumorigenic and proangiogenic factor in
cancer progression and has been associated with immune
disorders such as HIV.82 Overexpression of Galectin-1 was
observed to be linked to progression of many types of cancers,
including osteosarcoma, breast, lung and prostate cancers and
in melanoma. The secretion of Galectin-1 by tumors leads to
tolerogenic signaling and immune suppression. Therefore,
Galectin-1 is an emerging biomarker for the diagnosis, prog-
nosis and treatment plan of several cancers and interest is
arising in targeting Galectin-1-glycan interactions in the
attempt to overcome cancer mediated immunosuppression
(Table 2).83
Galectin-3 has the unique feature of being able to crosslink
its binding partners through the presence of an oligomeriza-
tion domain. Binding of Galectin-3 to glycoproteins has both
pro- and anti-apoptotic effects on T cells, dependent on its
localization. Intracellular Galectin-3 blocks apoptosis by
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stabilizing the mitochondrial membrane and preventing cyto-
chrome c release,70 while extracellular Galectin-3 binds to
glycoproteins such as CTLA-4 and Lag3 on the T cell surface,
leading to inhibition and cell death of activated T cells.71,72
Endogenous Galectin-3 produced by activated T cells is
recruited to the immunological synapse. There it negatively
regulates T cell activation by destabilizing the immunological
synapse through direct interactions with glycoproteins asso-
ciated with the T cell receptor, and by promoting downregu-
lation of the TCR.84,85 Another interesting finding is that
binding of Galectin-3 to antigen-specific activated CD8βT
cells inhibits their effector function within the tumor micro-
environment (Table 2).71
Selectins
Selectins play important roles during different stages of cancer
progression, including recruitment of leukocytes to the tumor
site, immune evasion mechanisms, dissemination and extra-
vasation. As L-Selectin is believed to be involved in the acqui-
sition of T cell effector function, it confers protective
antitumor immunity. Consistent with this, accumulation of
myeloid derived suppressor cells (MDSCs) was observed in
cancer patients and is known to suppress both the innate and
adaptive antitumor response through processes comprising
downregulation of L-Selectin.73 In contrast, L-Selectin present
on the surface of leukemia cells promotes cancer progression
in CLL patients by affecting their trafficking and distribution
abilities (Table 2).74
Siglecs
Siglec-15 is broadly upregulated on human cancer cells and
tumor-infiltrating myeloid cells, directly suppressing antigen-
specific T cell responses in vitro and in vivo.77 Tumor-
infiltrating CD11b+ cells from Siglec-15 KO mice significantly
promoted CD8+ T cell proliferation as well as cytokine secre-
tion compared to those from wild type mice (Table 2).77
Siglecs are expressed at very low levels on normal T cells.
Several recent reports demonstrate the expression of Siglec-9 on
tumor-infiltrating cytotoxic CD8+ T cells in multiple types of
cancers (colorectal, ovarian and non-small cell lung cancer
(NSCLC), and melanoma).75,76 These Siglec-9-expressing
tumor-infiltrating lymphocytes (TILs) as well as Siglec-9+
CD8+ T cells, in lower numbers in the peripheral blood of
melanoma patients and healthy donors, exhibited an effector
memory phenotype. Co-expression with several known inhibi-
tory T-cell receptors, e.g. PD-1, CTLA-4 and TIM-3, is seen.
Despite this inhibitory phenotype, functional responses of Siglec-
9+ CD8+ T cells to CD3/C28 costimulation are higher than those
observed for their Siglec-9− counterparts in vitro (Table 2).76
A note of caution
While all of the studies done have provided valuable insight
on the potential modulatory function of altered glycosylation
in T cell biology, it should be noted that many conclusions
have been drawn from rather simplified in vitro cellular
immunology assay systems. To what extend these insights
and alterations of glycans and their interactions with glycan
binding proteins have an impact in realistic in vivo models of
disease and in patients often remains to be established. The
manipulations of the surface glycome of T cells and/or tumor
cells affect the entire glycome in most cases, not restricted to
one particular glycosylated molecule. Hence, the overall effect
of such glycome engineering should still be considered highly
unpredictable and worthy of exciting further research.
Targeting the tumor or T cell glycome for therapeutic
purposes
Cancer immunotherapies targeting the interaction of
human T cells with tumor cells by use of agents that bind
to glycans or glycan binding proteins
Many studies have aimed to induce specific immune responses
against tumor-associated glycans and glycoproteins.86 For
Table 2. Role of glycan binding proteins in T cell cancer immunity.
GBP EFFECT PRO OR ANTI-TUMORIGENIC
GALECTINS Galectin-1 ● Induction of tolerogenic signaling and immune suppression68,69 PRO
Galectin-3
Intracellular (T-cell)
Extracellular
● Blocking T cell apoptosis70
● Negative regulation of T cell activation by destabilizing the immunological synapse
and by promoting downregulation of the TCR.
● Binding to CTLA-4 and Lag3 leads to inhibition and cell death of activated T cells71,72
ANTI
PRO
Galectin-9 ● Negatively regulates T cell immunity by binding to Tim-367 PRO
SELECTINS L-Selectin
On T cells
On leukemia cells
● Acquisition of T cell effector functions73
● Improved trafficking and distribution abilities (dissemination) (CLL patients)74
ANTI
PRO
SIGLECS Siglec-9
On TILs ● Effector memory T cells with higher functional responses after stimulation75,76 ANTI
Siglec-15
On tumor cells and TIMs ● Suppression of antigen-specific T cell responses77 PRO
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example, a high anti-glycan antibody response could be driven
by a combination of adjuvants and an optimization of T cell
help through the use of repetitive immunizations with
a glycopeptide-displaying particle resulting in the elicitation of
anti-glycopeptide-specific T cells.86 In another glycan-enhanced
tumor vaccination approach, the coupling of glycans such as
Lewis antigens to tumor antigens could facilitate internalization
of the antigen by DCs due to improved recognition by DC-
SIGN. This in turn favors antigen cross presentation and sti-
mulation of tumor-specific T cell responses.87 Recently,
a carbohydrate-based vaccine was developed for metastatic
breast cancer targeting the glycolipid Globo-H. The vaccine
induced antibodies to target not only Globo-H but also
SSEA3 and SSEA4. Together, these three targeted glycolipids
were found to be uniquely expressed not only on the cell
surface of breast cancer but on 15 additional cancer types,
broadening the application of this vaccine, which is currently
tested in a phase I clinical trial (NCT02310464).88,89
In a different approach, cell-based immunotherapy utilizes
living cells to harness the body’s natural immune system to
fight disease. Chimeric antigen receptors (CARs) have been
developed that recognize cancer-associated glycan epitopes of
glycolipids and glycoproteins, such as the Lewis y antigen
(Ley), the sialyl Tn O-glycan epitope (TAG72), disialoganglio-
side GD2 and a Tn glycoform of MUC-1.90
Interfering with the interaction of surface glycans and their
lectin receptors, for example by adding antibodies that block
tumor-associated glycan-lectin interactions is yet another strategy
which is explored as antitumor therapy and several applications
look very promising and/or are already used in the clinic.64,91–94
Considering the abundance of Siglec ligands on the sur-
face of tumor cells and the inhibitory nature of many
Siglecs, multiple studies have recently been initiated, inves-
tigating the effect of altering the levels of sialylation on
tumor cells.95 They are targeted using blocking antibodies,
aiming to improve cancer immunotherapy.96 Anti-Siglec-15
monoclonal antibody (targeting tumor-infiltrated macro-
phages-TIMs) inhibited the growth of established tumors
in murine models.77 A clinical trial is ongoing to test the
effect of an anti-human Siglec-15 mAB (NC318) in solid
tumors, with promising very early results recently
reported.97 Worth noting is that Siglec-15 KO mice do not
develop obvious physical abnormalities, which is consistent
with rare expression on normal tissues and suggests mini-
mal adverse effects for Siglec-15 blockade therapy. Recently,
also Siglec-9 was considered as interesting target for cancer
immunotherapy.75,76 Targeting immunologic checkpoints
that include dominant regulatory circuits confined to the
tumor microenvironment, such as Siglec-9/-15 receptor-
ligand interactions, allow to selectively unleash the restricted
repertoire of TILs and TIMs, while reducing the potential
for uncontrolled T cell activation and associated immune-
related adverse events.98
Interfering with Selectin and Galectin functioning can also
influence the interaction of T cells with tumor cells.95,99 For
example, interference with L-Selectin-mediated trafficking by
treating patients with idelalisib, a phosphoinositide-3-kinase
δ inhibitor, in high endothelial venules could limit dissemi-
nation of CLL to lymph nodes.74 Galectin inhibitors have
been evaluated in combination with chemotherapy drugs
(5-fluorouracil) against solid tumors in several clinical trials,
however, only one trial has been completed so far, suggesting
that not all Galectin inhibitors are effective.100 Given the
pleiotropic effect of galectins, there may be a narrow safe
dosage window, although data in humans remains scarce.
Immunotherapy using monoclonal antibodies blocking
immune checkpoint molecules has been combined with
Galectin inhibitors to enhance the therapeutic effect in one
study.100 TIM-3 inhibitors have shown similar efficacy as that
of PD-1 inhibitors in preclinical research and many clinical
trials are now focusing on the use of anti-TIM3 blocking
antibodies.101
Glycan-engineering and implications in immune
therapy
To date, the precise experimental adaptation of glycan struc-
tures on a specific protein in a living cell is most often not
possible, except for the removal or addition of glycosylation
sites. Therefore, instead of focusing on specific glycoproteins,
a systems approach is taken in which the structure of glycans
on the cell surface as a whole is perturbed. This allows to link
changes in overall cellular glycosylation with cellular fates and
functions, but often makes it more difficult to dissect the
precise molecular mechanisms underlying glycosylation-
mediated signaling events and the downstream cellular conse-
quences. Alteration of cellular glycosylation capacity has an
impact on multiple cell surface receptors, their biogenesis,
biophysical behavior and signal transduction. What is mea-
sured is the integrated result of all of these alterations on
cellular behavior. But of course, it is cellular behavior that
matters in the end for therapeutic effects. The ability to remo-
del glycans on the cell surface could hence lead to novel
approaches to manipulate cellular physiology and functional
behavior.
The potential of glycosylation engineering to enhance ther-
apeutics has been investigated and utilized extensively in the
field of protein biopharmaceuticals, for example in anti-
cancer antibodies.102,103 Cell-based therapies are emerging
fast in the treatment of diverse diseases, including autoim-
mune diseases and cancer. In order to enhance the function of
therapeutic cells, extensive studies are being performed seek-
ing for improved survival, proliferation and differentiation of
these cells. In the following sections, we will describe glycode-
sign strategies used to endow therapeutic cells with new
favorable properties and functions.
Genetic engineering approaches
Genetic engineering via gene knockdown, knockout, over-
expression, knock in or selective nucleotide mutations can
be used to target glycosylation enzymes or complete path-
ways in order to reduce or silence undesirable glycosyl-
transferase activities or to enhance certain aspects of
glycosylation.
These genetic engineering approaches are based on devel-
opments in the field of genome engineering.104–106 Although
these techniques are very versatile and give us the opportunity
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to make permanent cellular glycan modifications, it has to be
kept in mind that potential off-target effects, inefficient deliv-
ery systems, confounding epigenetic regulation of glycosyla-
tion pathways, compensatory glycan alterations and
unpredictable alterations in cellular physiology can have
a detrimental impact on the intended results. Fast develop-
ments in the genome editing field result in continually
improving and newly emerging tools, which should eliminate
several of these problems in the coming years.107
Some interesting results were already obtained using genetic
glycoengineering. For example, selectively removing conserved
N-glycosylation sites in the constant regions of TCRα and β-
chains increased the functional avidity (reflected by increased
cytokine secretion, lytic capacity and tumor cell recognition) of
T cells transduced with modified TCRs. This is caused by an
improved αβTCR multimerization and decreased TCR-MHC
dissociation, ultimately increasing the recognition of tumor
cells bearing the target antigen (Table 3).108
In another study, overexpression of rat ST6GalI in murine
and human T cell lines resulted in increased α-2,6-sialylation
of N-glycans, thereby shielding LacNAc residues from
Galectin-1 binding and reducing Galectin-1 induced cell
death of the T cells (Table 3).45
Using a genome-wide loss-of-function CRISPR-Cas9 based
screening method, Okada et al. identified FUT8 (the core
fucosyltransferase) as a positive regulator of cell-surface
expression of PD-1, a marker of T cell exhaustion.
Inhibition of FUT8 by genetic ablation reduced cell surface
expression of PD-1 and enhanced T cell activation and anti-
tumor immune responses (Table 3).109
Metabolic glycoengineering
Metabolic glycoengineering (MGE) involves the incorporation
of non-natural glycan constituents. This type of engineering is
often exploited in order to label glycans for the purpose of
imaging, tracking and identifying glycan structures.120 On the
other hand, the remodeling of glycan structures on the cell
surface can provide a powerful means to modulate cellular
functions and responses. In practice, living cells or even entire
organisms are supplemented with synthetic monosaccharide
precursors that either alter the natural flux through
a biosynthetic pathway or substitute natural metabolites with
non-natural analogs. These metabolites are processed by the
natural biosynthetic pathway, eventually leading to altered
glycoforms, potentially containing non-natural chemical
groups. This approach is rather convenient because the analog
can be directly added to the cell culture medium during
therapeutic cell cultivation. However, the large-scale synthesis
of the required monosaccharide analogs can turn out to be
very expensive to implement such glyco-engineering strategies
in real therapeutic cell manufacturing.
Inhibiting the biosynthesis of Galectin-1-binding
N-acetyllactosamine (LacNAc) glycans via systemic delivery
of non-natural fluorinated carbohydrate analogs increases the
number of infiltrating tumor-specific cytotoxic T cells and
intratumoral IFN-γ expression in mice.110 Alternatively, intra-
tumoral injection of thiodigalactoside, a Galectin-binding var-
iant of lactose with enhanced glycosidase stability, leads to an
increase in tumor-infiltrating cytotoxic T cell numbers and
reduced tumor growth (Table 3).111 Furthermore, the use of
Table 3. Examples of glycan-engineering and its implications in immune therapy.
Intervention Effect
GENETIC ENGINEERING Deletion of N-glycosylation
sites in TCR chains
● Increased functional avidity by improved TCR multimerization and decreased TCR-MHC
dissociation108
Overexpression of ST6GalI
(increased α-(2,6) sialylation)
● Shielding LacNac residues from Galectin-1 binding, reducing Galectin-1 induced cell death of
T cells45
Genetic ablation of FUT8 ● Reduced cell surface expression of PD-1 and enhanced T cell activation109
METABOLIC
GLYCOENGINEERING
Inhibition of LacNAc synthesis
Addition of Galectin-binding
variant of lactose
● Increased number of infiltrating tumor-specific CD8+ T cells and intra-tumoral IFN-γ
expression110
● Increased TIL numbers and reduced tumor growth111
Inhibition of fucosylation and
sialylation
Sialic acid biosynthesis
blockade
● Decreased Selectin ligand synthesis and impaired cancer cell adhesion and migration in vitro
and prevention of metastasis in vivo112
● Enhanced T cell killing capacity113
Enhanced N-glycan branching ● Control of the T cell immune response114
CHEMOENZYMATIC
GLYCOENGINEERING
LacNAc labeling
LacNAc modification with
antibodies to generate
antibody-T cell conjugate
● Biophysical probe for imaging or glycomics analysis115
● Increased tumor targeting capacity and resistance to inhibitory signals116
Fucosyltransferase treatment
of regulatory T cells
● Increased expression of sLex antigens leading to improved trafficking, homing and
engraftment117
PNGaseF treatment of
regulatory T cells
● Increased proliferation of naïve and memory T cells118
Sialidase treatment of
cytotoxic T cells
● Increased T cell activation and cytolytic activity119
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fluorinated fucose and sialic acid analogs blocks protein fuco-
sylation and sialylation, leading to suppression of Lewis-x
(Lex) and sLex antigen biosynthesis.112 This impairs cancer
cell adhesion and migration in vitro and prevents metastasis
formation in vivo in mice.121 Additionally, sialic acid bio-
synthesis blockade enhances tumor cell – T cell interactions
and enhances the killing of tumor cells by cytotoxic T cells
(Table 3).113 Further research is needed to unravel the
mechanisms underlying the enhanced susceptibility of sialic
acid-depleted tumor cells to killing by cytotoxic T cells. One
hypothesis is that removal of negatively charged sialic acids
could influence the biophysical interaction between tumor
cells and T cells, for instance by affecting MHC I–TCR inter-
actions and subsequent signaling events.26,122 In inflammatory
bowel disease, metabolic supplementation of mucosal T cells
with GlcNAc leads to enhancement of N-glycosylation
branching on the TCR, thereby controlling the T cell immune
response (Table 3).114
In an alternative metabolic glycoengineering approach,
monosaccharide analogs are used to introduce non-natural
chemical moieties (such as ketones, azides, alkynes, thiols, …)
in glycans, enabling bioorthogonal conjugation of small mole-
cules such as toxins, drugs, imaging agents and polymers via
click chemistry. Using this bioorthogonal click chemistry,
a library of more than 60 different cell lines was generated
with different sialic acid modifications, leading to dramatic
increases in binding with Siglec family members. This enabled
the study and steering of the complex interactions between
sialic acid and their Siglec binding partners.123 Whether any
of this will be of relevance for safe enhanced cellular immu-
notherapy awaits further experimentation. Glycometabolic
bioorthogonal chemistry can be utilized to establish a highly
efficient viral transduction system for human primary
T lymphocytes, thereby showing a great potential for clinical-
engineered T-lymphocyte manufacturing.124
In order to conclude this section, it is important to point
out the complex and often-unpredictable interplay between
metabolism, genetics and cell fate occurring during metabolic
glycan engineering. Only further rigorous experimentation in
therapy-relevant cell manufacturing conditions and suitable
animal models of cancer (in particular using patient-derived
human tumor cells) may reveal the concepts that are promis-
ing for translation into therapy.
Chemoenzymatic glycoengineering
Chemoenzymatic glycan labeling and modification is an emer-
ging valuable tool to modify the glycan structures within a cell,
and is complementary to metabolic glycan engineering. Instead
of using the cell’s own glycan biosynthetic machinery to incor-
porate unnatural monosaccharides, chemoenzymatic glycoengi-
neering utilizes a recombinant glycosyltransferase to transfer
natural or unnatural monosaccharides equipped with
a bioorthogonal chemical tag to glycoconjugates, thereby endow-
ing them with novel structural characteristics and function.125
As described in the previous section, imaging glycans
in vivo is possible using bioorthogonal chemical reporter
strategies in which cells or even complete organisms are
supplemented with azide- or alkyne-tagged monosaccharide
precursors. A limitation of this strategy is that each mono-
saccharide is normally incorporated into a multitude of
different glycans, making it impossible to label higher
order glycans uniquely by feeding the biosynthetic pathway
with unnatural monosaccharides. Chemoenzymatic
approaches were reported for the labeling of complete cell
surface glycans containing LacNAc. In this approach,
recombinant microbial α-(1,3)-fucosyltransferase treatment
was used to label the LacNAc moieties with clickable fucose
analogs, which can be used as biophysical probes for ima-
ging or glycomics analysis. By probing LacNAc levels in this
way, it was possible to differentiate lymphocytes exhibiting
different activation states (Table 3).115
Ex vivo enzymatic treatment of immune cells has led to pro-
mising results in the field of anti-graft versus host disease adoptive
cell therapy. When regulatory T cells were treated with recombi-
nantly produced Fucosyltransferase-VI (FUT6) and the GDP-
Fucose donor substrate, an increase in sLex antigens was observed
on their cell surface, leading to an improvement in trafficking,
homing to the site of inflammation and engraftment of these
regulatory T cells (Table 3).117 Similarly, increased homing of
CAR-T cells to the bone marrow was observed following the
same ex–vivo treatment with FucTVI.126 When regulatory
T cells are enzymatically treatedwith PNGaseF to partially remove
N-glycans expressed on the surface, their capacity to suppress
early activation events in the spleen is substantially impaired,
leading to proliferation of naive and memory T cells
(Table 3).118 Furthermore, pretreatment of cytotoxic T cells with
either a Clostridium perfringens sialidase or an O-linked glycopro-
tein endopeptidase increased activation and cytolytic capacity
in vitro, indicating that glycosylated surface proteins can hinder
cytotoxic T cell activation and functioning (Table 3).119 More
recently, a single-step chemoenzymatic approach for the develop-
ment of antibody-cell conjugates was described. In this approach,
the therapeutic T cell surface glycocalyx is ex vivo modified at
LacNAc moieties with tumor-targeting antibodies. This is made
possible by the use of a GDP-fucose analog, conjugated by click
chemistry at the C6 position to a full length antibody, using
Helicobacter pylori α-1,3-fucosyltransferase. In this way, T cells
obtain specific tumor targeting capacity and resistance to inhibi-
tory signals produced by tumor cells.116
Concluding remarks
Despite the clinical success of antibodies against immune
checkpoints, only a subset of people exhibits sustained
responses. This can be explained by the fact that anti-tumor
immunity is influenced by a continuously evolving complex
interplay of host, tumor and environmental factors governing
the strength and timing of the anticancer response.
These factors combine to produce a ‘cancer-immune set
point’, which can be seen as the equilibrium between the
factors that promote or suppress anticancer immunity, that
can predict responses to immunotherapy (for a review, see
ref.127). It is now clear that glycan structures and their binding
proteins play very important roles in this.
Glyco-engineering of the tumor cell – immune cell interface
thus provides exciting perspectives for improving immunother-
apy in the future. Due to the complexity, species differences and
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pleiotropic effects of manipulating this interface, the predict-
ability of such glyco-engineering outcomes by extrapolation
from in vitro or simple animal model systems will likely be
low. It will inspire exciting research in glyco-oncology in models
that are even more faithful representations of human disease,
for many years to come. The first drugs that target glyco-
components of the tumor-immune interface are in full clinical
development, and it is likely that many more will follow.
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Abbreviations
ADCC antibody-dependent cellular cytotoxicity
Asn asparagine
ASGPR Asialoglycoprotein receptor
Figure 2. In this review, we discuss the role of different types of glycans decorating the surface of T cells, and their binding to GBPs and resulting functions. Central in
the figure, several mammalian glycoforms that can occur on the T cell surface are shown. Above them, the GBPs that bind to them and the effects they have on
T cells are outlined and below them we elaborate on the effects of therapeutic interventions on the glycan composition. The color of the arrows relates to the
glycoforms, as indicated centrally in the figure, and the direction indicates decreased or increased expression of those glycoforms. The text next to the arrow then
explains the effects on the T cell, resulting from the indicated changes in the glycoforms.
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CAR chimeric antigen receptor
CD62E E-selectin
CD62L L-selectin
CD62P P-selectin
CLR C-type Lectin receptor
CRD carbohydrate recognition domains
CRISPR-CAS Clustered Regularly Interspaced Short Palindromic
Repeats
CTLA-4 cytotoxic T-lymphocyte-associated antigen-4
DC dendritic cell
DC-SIGN dendritic cell-specific ICAM-grabbing non-integrin
DN double negative
DP double positive
ER endoplasmic reticulum
Fut6 α1-3 fucosyltransferase VI
Fut7 α1-3 fucosyltransferase VII
GA Golgi apparatus
GalNac N-acetylgalactosamine
GBP glycan-binding protein
Gcnt1 β1-6 N-acetylglucosaminyltransferase-I
GlcNAc N-acetylglucosamine
HCV hepatitis C virus
ITIM immunoreceptor tyrosine-based inhibition motif
LacNac N-acetyllactosamine
Lex Lewis x antigen
Ley Lewis y antigen
MAG myelin-associated glycoprotein
MBP mannose-binding protein
MDSC myeloid derived suppressor cell
Mgat5 β1,6 N-acetylglucosaminyltransferase V
MGE metabolic glycoengineering
MHC major histocompatibility complex
MMR macrophage mannose receptor
NSCLC non-small cell lung cancer
OGT O-GlcNAc transferase
PD-1 programmed cell death protein-1
PD-L1 programmed death ligand-1
PNA peanut agglutinin
PSGL-1 P-selectin glycoprotein ligand-1
Siglec sialic acid-binding immunoglobulin-type lectins
sLex sialyl-Lewis-X
SNA Sambucus nigra
SSEA stage-specific embryonic antigen 3
ST3Gal1 β-Galactoside α2,3-Sialyltransferase 1
ST6Gal1 β-Galactoside α2,6-Sialyltransferase 1
TALEN Transcription Activator-Like Effector Nucleases
TCM central memory T cell
TCR T cell receptor
TEM effector memory T cell
TIM tumor-infiltrated macrophage
TIL tumor-infiltrating lymphocyte
Treg regulatory T cell
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